AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$DH

Definitive Healthcare Reports Financial Results for Third Quarter 2026

Definitive Healthcare Corp. (DH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definitive Healthcare Reports Financial Results for Third Quarter 2026 Third Quarter Revenue Within Guidance Range; Profit Surpasses Expectations Framingham, MA (November 5, 2026) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH),

Original reporting
SEC EDGAR 8-K
Published Nov 5, 2026, 9:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$DH
Bearish
medium confidence
Mentioned
$DH
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DHBearishMed
01

Why it matters

The earnings miss and lack of guidance may trigger short‑term selling pressure, while the Advent interest could create upside potential if a deal materializes.

02

Market read

Primary earnings disclosure for a micro‑cap healthcare data firm; modest impact on sector sentiment.

03

What to watch

New customer wins and upsell to a malpractice insurer could provide future revenue tailwinds not reflected in the quarter.

Relevance 7/10Novelty 7/10Timing: after-hours

Background

Definitive Healthcare Corp. filed a Form 8‑K reporting its Q3 2026 financial results, including a revenue decline and net loss, and disclosed a pending non‑binding acquisition interest from Advent International.

Company-level read

Ticker impact

$DHBearishMedium confidence
Context

Q3 2026 results show 9% revenue decline to $54.7M and a net loss of $5.4M, indicating weaker performance.

Expected impact

likely downside as market prices in weaker revenue and loss

Evidence & confidence

Revenue fell 9% YoY and the company posted a net loss, while adjusted earnings slipped slightly; no guidance was provided, increasing uncertainty.

Market effects

Sector

May weigh on healthcare data and analytics sector as peers could face similar revenue pressure.

Regional

Limited to US-listed microcap investors; minimal broader regional effect.

Global

Low global relevance; primarily a company-specific earnings update.

Counterpoint

What could challenge this read

Adjusted EBITDA remains healthy at 29% of revenue, suggesting operational resilience despite top-line decline.

Key entities

  • company
    Definitive Healthcare Corp.

    Healthcare market data and analytics provider (NASDAQ: DH).

  • investor
    Advent International

    Private equity firm that submitted a non‑binding indication of interest to acquire DH.

Read at source← All news

Related articles

$IONSHighAI 9/10

Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

rttnews.com
$DHMedAI 8/10

Advent Proposed $1.02 Cash Take-Private of Definitive Healthcare:

Definitive Healthcare Corp. (DH) received a non-binding take-private proposal from Advent International for $1.02 per share. The offer is subject to review by a special committee and requires founder Jason Krantz's equity rollover. No binding agreement exists yet, and Advent may withdraw or modify the proposal.

hedgeco.net
$DHMedAI 8/10

Definitive Healthcare (DH) Q2 2026 Earnings Call

Definitive Healthcare (DH) reported Q2 FY26 revenue of $55.2 million, down 9% year over year, with adjusted EBITDA of $14.6 million and net dollar retention improving for a second straight quarter. Subscription revenue fell 9% to $52.8 million. Full-year guidance: revenue $220-$222 million and adjusted EBITDA $57-$59 million; Q3 revenue $54-$55 million.

fool.com
$DHHigh

Definitive Healthcare Reports Financial Results for Second Quarter 2026

Definitive Healthcare Corp. (DH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definitive Healthcare Reports Financial Results for Second Quarter 2026 Second Quarter Revenue Within Guidance Range; Profit Surpasses Expectations Framingham, MA (August 10, 2026) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH),

SEC EDGAR 8-K